Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
965.45 K
Value Traded
-
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.59 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
55.03 M
Float Shares
-
Insiders
-
Institutions
13.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LYCA Catalyst Timeline
Dated clinical, regulatory and corporate events for Lycia Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lycia Therapeutics, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How LYCA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LYCA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LYCA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LYCA for Q2 2026. | ||||
LYCA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LYCA ranks across every disease it competes in
Competitive Position is a premium feature
See how LYCA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLYCA News
-LYCA
Oct 26, 2026▼ -3.8%today
Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Lycia Therapeutics closed its upsized initial public offering, raising about $365.1 million by selling 20,286,000 shares at $18.00 each. The offering included an additional 2,646,000 shares purchased by underwriters. Lycia's common stock began trading on the Nasdaq Global Select Market on October 23, 2026.
Read more →-LYCA
Oct 22, 2026▼ -3.8%today
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
Lycia Therapeutics announced the pricing of its upsized IPO, offering 17,640,000 shares at $18.00 each. The gross proceeds are expected to be around $317.5 million. The company's stock will start trading on the Nasdaq Global Select Market on October 23, 2026, under the ticker 'LYCA'. The offering is set to close on October 26, 2026.
Read more →About Lycia Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next LYCA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime